Current Status of Digital Therapeutics for Mild Cognitive Impairment

System Development and Market Expansion from Diagnosis to Treatment

It is well known that Japan is becoming a super-aging society, but the same is true for other developed countries. In the U.S., for example, there are currently 5.8 million patients with Alzheimer's disease (AD), and this number is estimated to increase to 13.8 million by 2050. Pre-consultation Screening with Digital Therapeutics is needed (see the previous article, “Digital Screening for Cognitive Impairment”) all the more that the percentage of patients reaching for medical care is small. As the need for this technology increases year by year, it also means that the market for dementia diagnosis and treatment will expand, and many people are probably thinking of ways to monetize it.

In the U.S., start-up research is taking off, backed by huge research funding. For example, neuroFit, a San Francisco-based company, is collaborating with the National Institutes of Health (NIH) on a study to screen for mild cognitive impairment (MCI) based on eye movements.

(Continue to the next)

The information contained in this article is compiled by the respective authors based on publicly available information. We assume no responsibility whatsoever for any damage or disadvantage caused by actions taken based on such information. Unauthorized reproduction of articles, photos, charts, etc. is prohibited.
Copyright © 2021 LSMIP office / CM Plus Corporation